S100P (S100 calcium binding protein P)

2008-07-01   Sayka Barry , Tatjana Crnogorac-Jurcevic 

Institute of Cancer, Barts, The London, Queen Marys School of Medicine, Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom





S100P gene contains two exons and one intron. Genomic size of 3,332 bases.


1279 bases mRNA; 288 bases coding sequences. The transcript is on Chromosome 4 at location 6,745,697-6,749,797.


None identified.



S100P protein consists of 95 amino acids with a molecular weight of 10.4 kDa.
S100P is a Ca2+ binding protein that belongs to S100 family ("Soluble in 100% saturated solution with ammonium sulfate") which was first isolated from human placenta and is therefore designated as "P". S100 family includes at least 26 members, which are thought to be expressed only in vertebrates and are present in a tissue and cell-specific manner. S100 proteins are characterized by common structural motifs including 2 EF-hands (helix-loop-helix calcium binding domains) with different affinities for calcium ions, a central hinge region and the C-terminal extension. The N-terminal half of the protein contains an unconventional EF hand that binds calcium with lower affinity, while the C-terminal is canonical and binds calcium with high affinity. The connecting hinge region and the C-terminal extension are the most variable regions and thus determine the functional specificity of S100 family members, including S100P. In addition to Ca2+, S100P also binds Zn2+ and Mg2+ and can form homo- and heterodimers.


S100P is expressed in various normal tissues including placenta, lung, heart, kidney, bladder, skeletal muscle, bone marrow, spleen, mammary epithelium, epidermis, prostate gland, gastric and intestinal mucosa, and malignant tissues such as pancreatic ductal adenocarcinoma, pancreatic intraductal papillary mucinous neoplasm, non-small-cell lung cancer, melanoma, gastric adenocarcinoma, ovarian, breast, colon and prostate carcinoma as well as in the body fluids such as tear, pancreatic juice, blood and urine.


Cytoplasm, nucleus, also secreted in the culture media.


S100P is involved in diverse biological functions but the exact role or mechanism of its action is still largely unknown. Upon binding of calcium ions S100P undergoes a conformational change that results in an exposure of a hydrophobic surface which allows the interaction with specific target proteins. To date, several S100P interacting partners have been identified including S100P binding protein S100PBP, EZR, S100A1, ECD, CacyBP, RAGE, S100Z and S100A6, but the consequences of their interactions are not fully understood.


S100P shares 50% sequence identity with human S100A1 and 44% identity with S100B.



Mutations have not been reported.

Implicated in

Entity name
S100P has been associated with the progression of several types of cancer including pancreatic, prostate, non-small cell lung, breast, and colorectal cancer.
S100P has been implicated in migration, invasion, proliferation and survival of cancer cells in vitro and increased tumour growth in vivo. In fibroblasts, S100P has been shown to function as an autocrine growth and survival factor that enhanced cell proliferation and survival by activating RAGE receptor through MAPK and NF-kB signaling.
Entity name
Pancreatic cancer
The up-regulation of S100P is an early event in the development of pancreatic cancer and its expression increases throughout the progression of pancreatic intraepithelial neoplasia (PanINs) to invasive pancreatic ductal adenocarcinoma. S100P plays a critical role in the maintenance of the structural organization of intermediate filaments (cytokeratins 8, 18 and 19) and actin cytoskeleton, and its over-expression changes the phosphorylation status of the actin regulatory protein cofilin. Over-expression of S100P also increases the expression of S100A6 and cathepsin D, both of which are involved in cellular invasion. As S100P is expressed early in pancreatic ductal adenocarcinoma and is secreted into body fluids, it can serve as an useful diagnostic marker.
Entity name
Prostate cancer
In prostate cancer over-expression of S100P increases cell growth both in vitro and in vivo. S100P over-expression also up-regulates androgen receptor that leads to prostate cancer progression. Its expression has also been associated with poor clinical prognosis of patients with this malignancy.
Entity name
Non-small-cell lung cancer
Higher levels of S100P have been correlated with progression to metastasis and decreased survival in patients with lung cancer. This may also serve as a predictor of distant metastasis and poor survival in non-small cell lung carcinomas.
Entity name
Colorectal cancer
In colon cancer, expression of S100P correlates with resistance to chemotherapy and has also been associated with doxorubicin resistance in colon cancer cell lines.
Entity name
Breast cancer
S100P has been associated with immortalization of breast cancer cells in vitro and tumour progression in vivo. Higher level of S100P expression has also been correlated with decreased survival in patients with breast cancer.
Entity name
Other cancer types
S100P is also expressed at higher levels in gastric, ovarian and cervical carcinomas.


Pubmed IDLast YearTitleAuthors
169488362006The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins.Adachi J et al
160618482005S100P promotes pancreatic cancer growth, survival, and invasion.Arumugam T et al
184521692008Functional evidence implicating S100P in prostate cancer progression.Basu GD et al
16338091992S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties.Becker T et al
121182442002Gene-expression profiles predict survival of patients with lung adenocarcinoma.Beer DG et al
96359211998Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression.Bertram J et al
129500182003Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.Crnogorac-Jurcevic T et al
153138922004S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer.Diederichs S et al
126450022003Intracellular and extracellular roles of S100 proteins.Donato R et al
156320022005Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.Dowen SE et al
120423132002CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family.Filipek A et al
175871382007RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.Fuentes MK et al
106395642000S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo.Guerreiro Da Silva ID et al
119437092002Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.Iacobuzio-Donahue CA et al
146724112003Characterization of the tissue-specific expression of the s100P gene which encodes an EF-hand Ca2+-binding protein.Jin G et al
128080362003Ca2+-dependent binding and activation of dormant ezrin by dimeric S100P.Koltzscher M et al
181627742008Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.Lin F et al
127502932003Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.Logsdon CD et al
118888862002Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays.Mousses S et al
147674732004Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection.Nakamura T et al
127464582003Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins.Nowotny M et al
170006742006S100P is an early developmental marker of pancreatic carcinogenesis.Ohuchida K et al
182822792008The calcium-binding protein S100P in normal and malignant human tissues.Parkkila S et al
147162962004Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.Sato N et al
164240592006Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.Wang G et al
178757032007The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.Whiteman HJ et al
125074802003The crystal structure at 2A resolution of the Ca2+ -binding protein S100P.Zhang H et al
169013382006Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors.de Souza GA et al

Other Information

Locus ID:

NCBI: 6286
MIM: 600614
HGNC: 10504
Ensembl: ENSG00000163993


dbSNP: 6286
ClinVar: 6286
TCGA: ENSG00000163993


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
Immune SystemREACTOMER-HSA-168256
Innate Immune SystemREACTOMER-HSA-168249
Neutrophil degranulationREACTOMER-HSA-6798695

Protein levels (Protein atlas)

Not detected


Pubmed IDYearTitleCitations
146176292004S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE).87
160618482005S100P promotes pancreatic cancer growth, survival, and invasion.72
174860812007Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.49
147162962004Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.41
213272972011Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis.32
178757032007The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D.27
184521692008Functional evidence implicating S100P in prostate cancer progression.24
223993002012S100P dissociates myosin IIA filaments and focal adhesion sites to reduce cell adhesion and enhance cell migration.23
211778632011S100P is a novel interaction partner and regulator of IQGAP1.22
187254082008Characterization of the Ca2+ -regulated ezrin-S100P interaction and its role in tumor cell migration.21


Sayka Barry ; Tatjana Crnogorac-Jurcevic

S100P (S100 calcium binding protein P)

Atlas Genet Cytogenet Oncol Haematol. 2008-07-01

Online version: http://atlasgeneticsoncology.org/gene/42196/s100pid42196ch4p16